ICOS and colorectal carcinoma: Lastly, the expression of other checkpoint molecules (ICOS, TIM-3, LAG-3, GITR and OX40) and their role in T cell inhibition or activation in the context of CRC may explain the resistance to currently used PD-1/PD-L1 inhibitors [20].